Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FREEDOM-EXT: Oral Treprostinil Extension in PAH
NCT01027949Phase 3Completed
- Sponsor
- United Therapeutics Corporation
- Start
- Jan 2007
- Primary completion
- Feb 2020
- Modality
- Orthosteric Ligands
- Countries
- 20
01
Overview
A Phase 3 trial of treprostinil in pulmonary arterial hypertension (PAH), sponsored by United Therapeutics Corporation. Started Jan 2007; status: completed.
02
Drugs
treprostinil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT01027949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01027949.